Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Nov 28 2018

Full Issue

Has FDA's 'First In The World' Ambition Contributed To Years Of High-Profile Safety Problems With Medical Devices?

Balancing innovation, regulation and a symbiotic relationship with the medical industry it oversees is a tricky task for the agency. The Associated Press takes a look at the FDA's push for quick approvals and how that may have lead to problems with current devices on the market.

The Associated Press: At FDA, A New Goal, Then A Push For Speedy Device Reviews

Dr. Jeffrey Shuren was adamant: The United States would never cut corners to fast-track the approval of medical devices. "We don't use our people as guinea pigs in the U.S.," Shuren said, holding firm as the new director of the U.S. Food and Drug Administration's medical devices division. Again and again in 2011 — four times in all — Shuren was summoned before Congress. Lawmakers accused the agency of being too slow and too demanding in reviewing new devices like heart valves and spinal implants, driving U.S. manufacturers overseas where products faced less rigorous review. Each time, he pushed back. And yet the next year, Shuren and his team adopted an approach that surprised even some of his closest colleagues: The FDA would strive to be "first in the world" to approve devices it considered important to public health. (Perrone, 11/27)

The Associated Press: Insulin Pumps Have Most Reported Problems In FDA Database

When Polly Varnado's 9-year-old daughter was diagnosed with Type 1 diabetes, it didn't take long for the family to hear about insulin pumps. In September 2012, the girl picked out a purple one — her favorite color. Over the next seven months, she proceeded to be hospitalized four times in a McComb, Mississippi medical center with high blood sugar. But when Varnado asked about all her daughter's problems, she said, her doctor blamed user error. (Mohr and Weiss, 11/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF